{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T21:30:34Z","timestamp":1792963834623,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.lungcan.2015.04.008","type":"journal-article","created":{"date-parts":[[2015,4,26]],"date-time":"2015-04-26T01:24:29Z","timestamp":1430011469000},"page":"57-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies"],"prefix":"10.1016","volume":"89","clinical-trial-number":[{"clinical-trial-number":"nct00718809","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Matthew A.","family":"Gubens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie San","family":"Pedro-Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy K.","family":"Althouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Loehrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2015.04.008_bib0110","first-page":"161","article-title":"Primary mediastinal malignancies: findings in 219 patients","volume":"170","author":"Temes","year":"1999","journal-title":"West J Med"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0115","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.athoracsur.2008.12.095","article-title":"Thymomas: review of current clinical practice","volume":"87","author":"Tomaszek","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0120","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.11099","article-title":"Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies","volume":"105","author":"Engels","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0125","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.6004\/jnccn.2010.0096","article-title":"Thymic malignancies","volume":"8","author":"Ettinger","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0130","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","article-title":"Chemotherapy for invasive thymoma. A 13-year experience","volume":"68","author":"Fornasiero","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0140","first-page":"7079","article-title":"A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma","volume":"24","author":"Loehrer","year":"2006","journal-title":"ASCO Annu Meet Proc"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0145","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0150","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1999.17.9.2737","article-title":"Treatment of invasive thymoma with single-agent ifosfamide","volume":"17","author":"Highley","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0155","doi-asserted-by":"crossref","first-page":"7906","DOI":"10.1038\/sj.onc.1208160","article-title":"Src family kinases, key regulators of signal transduction","volume":"23","author":"Parsons","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0160","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0065-1281(99)80042-7","article-title":"Immunohistochemical study of tyrosine phosphorylation signaling in Hassall's corpuscles of the human thymus","volume":"101","author":"Nishio","year":"1999","journal-title":"Acta Histochem"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0165","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1128\/MCB.4.12.2705","article-title":"Characterization of the protein apparently responsible for the elevated tyrosine protein kinase activity in LSTRA cells","volume":"4","author":"Voronova","year":"1984","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0170","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1038\/sj.onc.1203912","article-title":"Role of Src expression and activation in human cancer","volume":"19","author":"Irby","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0175","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1634\/theoncologist.2010-0408","article-title":"Current status of SRC inhibitors in solid tumor malignancies","volume":"16","author":"Puls","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0180","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s10637-012-9809-7","article-title":"First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours","volume":"31","author":"Fujisaka","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0185","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1158\/1078-0432.CCR-10-0748","article-title":"Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors","volume":"16","author":"Baselga","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0190","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/bjc.2012.158","article-title":"Phase I study of saracatinib (AZD0530) in combination with paclitaxel and\/or carboplatin in patients with solid tumours","volume":"106","author":"Kaye","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0195","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0200","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0205","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2015.04.008_bib0210","doi-asserted-by":"crossref","first-page":"S365","DOI":"10.1097\/JTO.0b013e3181f22d01","article-title":"International thymic malignancies interest group: a way forward","volume":"5","author":"Detterbeck","year":"2010","journal-title":"J Thorac Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950021500207X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950021500207X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:01:54Z","timestamp":1566604914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950021500207X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S016950021500207X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.04.008","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}